Effects of insulin sensitizers on plaque vulnerability associated with elevated lipid content in atheroma in ApoE-knockout mice

Acta Diabetologica

Volumn 41, Issue 1, 2004, Pages 25-31

  Cefalu, W T ^a   Wang, Z Q ^a   Schneider, D J ^a   Absher, P M ^a   Baldor, L C ^a   Taatjes, D J ^a   Sobel, B E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Atherosclerosis; Diabetes; Glucose; Insulin; Lipids

Indexed keywords

APOLIPOPROTEIN E; CARBOHYDRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN SENSITIZING AGENT; LIPID; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HEART MUSCLE ISCHEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LASER MICROSCOPY; LIPID COMPOSITION; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; WEIGHT GAIN;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CAROTID STENOSIS; DIET, ATHEROGENIC; DISEASE SUSCEPTIBILITY; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL;

EID: 1642341897     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00592-004-0140-4     Document Type: Article

References (33)

1. Johansen OE, Birkeland KI (2003) Preventing macrovascular disease in patients with type 2 diabetes mellitus. Am J Cardiovasc Drugs 3(4):283-297
2. Howard BV, Magee MF (2000) Diabetes and cardiovascular disease. Curr Atheroscler Rep 2:476-481
3. Haffner SM (2000) Coronary heart disease in patients with diabetes. N Engl J Med 342:1040-1042
4. - (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
5. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE (2002) Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 53:538-549
6. Reaven GM (2002) Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 4[Suppl 1]:13-18
7. Haffner SM (2000) Coronary heart disease in patients with diabetes. N Engl J Med 342:1040-1042
8. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93:1809-1817
9. Plutzky J, Viberti G, Haffner S (2002) Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 16:401-415
10. Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K (2001) Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158:113-119
11. Hsueh WA, Law RE (2001) PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21:1891-1895
12. Raji A, Plutzky J (2002) Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep 4:514-521
13. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N (2001) Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21:372-377
14. Weng W, Breslow JL (1996) Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci U S A 93:14788-14794
15. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353
16. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM (1994) Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439
17. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA (1996) Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905
18. Pasceri V, Wu HD, Willerson JT, Yeh ET (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101:235-238
19. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
20. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL (1999) Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19:2094-2104
21. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
22. Li W, Tse JY, James AE, Lik-Wang L, Chi-Kwan Y, Man-Po C, Chung SC (2001) Delivery and scavenging system for small animal inhalational anesthesia. J Surg Res 99:175-178
23. Russell JC, Graham SE, Dolphin PJ (1999) Glucose tolerance and insulin resistance in the JCR: LA-corpulent rat: effect of miglitol (Bay m1099). Metabolism 48:701-706
24. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC (2002) Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 132:1107-1114
25. Taatjes DJ, Wadsworth MP, Schneider DJ, Sobel BE (2000) Improved quantitative characterization of atherosclerotic plaque composition with immunohistochemistry, confocal fluorescence microscopy, and computer-assisted image analysis. Histochem Cell Biol 113:161-173
26. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA (1987) Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231-240
27. Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:46-471
28. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ros R (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14:133-140
29. Reddick RL, Zhang SH, Maeda N (1994) Atherosclerosis in mice lacking ApoE. Evaluation of lesional development and progression. Arterioscler Thromb 141:141-147
30. Tamminen M, Mottino G, Qiao JH, Breslow JL, Frank JS (1999) Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19:847-853
31. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820
32. www.Bari2d.org; Accessed 27 January 2004
33. Cefalu WT, Wagner JD, Bell-Farrow AD, Edwards IJ, Terry JG, Weindruch R, Kemnitz JW (1999) Influence of caloric restriction on the development of atherosclerosis in nonhuman primates: progress to date. Toxicol Sci 52:49-55